A5073828154- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
- Cardiovascular Function and Risk Factors
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Economic Sanctions and International Relations
- Congenital Heart Disease Studies
- Renin-Angiotensin System Studies
- COVID-19 Clinical Research Studies
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
National Medical Research Center of Cardiology
2018-2021
Aim. The aim of current study was to estimate the economic burden chronic thromboembolic pulmonary hypertension (CTEPH) in Russia based on patient registry. Materials and methods. Cost illness data derived from CTEPH registry that developed at Division FSBI “National Medical Research Center Cardiology”. Demographic clinical characteristics were analyzed with descriptive statistic performed state perspective bottom-up approach. Bootstrapping used for calculation average costs per...
Currently, treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic (CTEPH) is focused on three signaling pathways: the NO pathway, endothelin prostacyclin pathway. Riociguat only representative stimulators soluble guanylate cyclase (sGC) class that approved for PAH inoperable persistent/recurrent CTEPH. The review presents data from clinical trials showing a positive effect riociguat functional hemodynamic profile patients with In recent years there has been much...
Chronic thromboembolic pulmonary hypertension (CTEPH) is a precapillary type of with chronic obstruction large and medium branches arteries along secondary alterations in microcirculation, which cause progressive increases vascular resistance arterial pressure ensuing severe right heart dysfunction failure. Pulmonary thromboendarterectomy (PTE) the treatment choice for CTEPH; however, this procedure available not all patients. Although surgery performed conditions centers advanced experience...
The article presents a clinical case of mild novel coronavirus infection COVID-19 complicated with bilateral interstitial pneumonia in female patient idiopathic pulmonary hypertension.
Objective. To study effectiveness and safety of generic bosentan use for 24 weeks in patients with pulmonary arterial hypertension (PAH). Materials methods. The included 42 patients. In 22 Bosentan therapy (Bosenex®, Sotex, Russia) was used the first time. 20 switching from original (Tracleer, Аctelion Pharmaceuticals Ltd., Switzerland) performed. were followed up 24±2 weeks. Results. After treatment percent functional class (FC) III decreased 55 to 30%, FC II increased 45 55%, some (15%)...
Objective : to conduct a comprehensive analysis of the clinical, functional, hemodynamic profile patients with pulmonary arterial hypertension associated congenital heart disease (PAH-CHD) according Russian Registry. Materials and methods The study involved 30 Eisenmenger syndrome, 25 PAH prevalent systemic-to-pulmonary shunts 26 after defect correction. All had been entered in registry (NCT03707561). A comparative parameters was held. diagnosis established by algorithm proposed guidelines...